Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Solid Moving Administrations for a Calm Movement - 2UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- 3Dinosaur collagen used to create one-of-a-kind handbag
- 4The 15 Most Powerful Forerunners in Business
- 5Charli xcx recorded original songs for 'Wuthering Heights' — what to know about the new album for Margot Robbie's film
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- Pick Your Favored method of transportation
- Vacuum Cleaners That Are Not difficult To Use For Home
- The best movies to watch this holiday season: Stream 'A Christmas Story Christmas,' revisit 'The Night Before' and discover 'The Baltimorons'
- 'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- Every year, she thanks the trooper for the arrest that led to her sobriety
- The Best 20 Tunes that Characterized an Age
- The 15 Most Rousing TED Chats on Self-awareness
- The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
